Angioplasty Balloons: How They Work, History, and Future Advances

Background

Angioplasty balloons are specialized medical devices inserted into narrowed arteries and inflated to restore blood flow. The full procedure, known as percutaneous transluminal coronary angioplasty (PTCA), has become the standard treatment for coronary artery disease since the 1980s. Compared with traditional bypass surgery, PTCA is less invasive, avoids opening the chest, and typically results in faster recovery times.

The procedure is performed under local anesthesia. The surgeon makes a small puncture in the femoral artery at the top of the leg, introduces a long catheter on a guidewire, and navigates it to the coronary artery under fluoroscopic guidance. Once the catheter reaches the blockage, a smaller balloon‑tipped catheter—about the thickness of a pencil lead—is advanced over the guidewire. The balloon is then inflated to a diameter of roughly 0.3 cm (an eighth of an inch). If the patient reports no pain, the balloon remains inflated for up to a minute, clearing the obstruction. After deflation, both catheters are withdrawn, and the patient is prescribed antithrombotic medication to reduce clot risk.

By the late 1990s, roughly 500,000 Americans underwent PTCA annually. While the technique has dramatically reduced the need for bypass surgery, up to 50 % of patients eventually require repeat procedures due to restenosis. Ongoing research focuses on preventing scar tissue formation and re‑narrowing of arteries.

History

Werner Forssmann pioneered cardiac catheterization in 1929 by inserting a catheter into his own heart—an act that earned him the Nobel Prize in 1956. In the 1960s, Charles Dotter explored arterial dilation with progressively larger catheters, laying groundwork for balloon angioplasty. The breakthrough came in 1977 when Andreas Gruentzig performed the first coronary balloon angioplasty at the University Hospital of Zurich. Gruentzig’s refined, flexible balloon catheter enabled safe, minimally invasive treatment of blocked coronary arteries. He introduced the technique to the United States in 1980, and within a decade, PTCA procedures exceeded 200,000 per year.

Raw Materials

Modern angioplasty balloons require a balance of strength and flexibility. Early balloons were made from flexible PVC; later generations employed cross‑linked polyethylene. Today, most balloons are constructed from polyethylene terephthalate (PET) or nylon. PET offers higher tensile strength, while nylon provides superior flexibility. Many balloons also feature specialized coatings—for lubrication, abrasion resistance, or drug delivery (e.g., heparin).

The Manufacturing Process

Extrusion

• Granulated polymer is fed into a heated barrel where it melts and is homogenized by a rotating screw.
• The molten plastic is extruded through a nozzle, forming a continuous tube that is cooled in a bath.
• After solidification, the tube is cut into pre‑forms of the required length.

Balloon Forming (Blow Molding)

• Each pre‑form is placed in a glassform and one end is sealed.
• Compressed air, combined with heated jaws, inflates the tube to the target diameter while the material is warmed to the optimal temperature.
• Computer‑controlled sensors manage pressure and temperature, ensuring uniform wall thickness.
• Once formed, the balloon is cooled, inspected, and removed from the glassform.

Inspection

• Visual and automated tests check for defects, wall‑thickness uniformity, and pressure tolerance.

Packaging

• Individual balloons are boxed, sealed, and shipped to a catheter manufacturer.
• There, the balloon is collapsed, glued or heat‑bonded to a catheter shaft, re‑inflated for a final test, and then sterilized for clinical use.

Quality Control

Because angioplasty balloons are life‑supporting devices, each unit undergoes rigorous, step‑by‑step inspection. The FDA mandates that manufacturers demonstrate safety and effectiveness before marketing. Consequently, production is labor‑intensive, with each balloon inspected individually rather than in large batches.

The Future

Re‑narrowing of arteries (restenosis) remains the most common reason for repeat PTCA. Current research focuses on drug‑coated balloons—often delivering heparin—to locally prevent scar tissue. Stents, small metal or polymer tubes placed concurrently with the balloon, also reduce restenosis rates. Emerging technologies aim to combine drug delivery and stent deployment in a single, integrated device, promising improved outcomes for both patients and clinicians.